Table 3.

Multivariable models of blood eosinophil count ≥ 300 cells/μL and exacerbation risk in ECLIPSE.

ECLIPSE
Factors associated with Exacerbation Rate	1 year		overall study period
	IRR (95% CI)	p value	IRR (95% CI)	p value
Age	1.01 (1.00–1.02)	0.008	1.01 (1.00–1.02)	0.01
Female	1.23 (1.10–1.38)	<0.001	1.31 (1.15–1.49)	<0.001
Non White race	0.82(0.56–1.18)	0.29	0.71(0.45–1.08)	0.12
SGRQ total score*	1.01 (1.01–1.01)	<0.001	1.01 (1.01–1.01)	<0.001
Post-bronchodilator FEV1 % predicted†	0.99 (0.98–0.99)	<0.001	0.98 (0.97–0.98)	<0.001
GERD	1.39 (1.24–1.56)	<0.001	1.36 (1.19–1.56)	<0.001
Current smoking	1.10(0.98–1.24)	0.11	1.21(1.06–1.39)	0.005
previous exacerbations	2.45 (2.18–2.74)	<0.001	2.87 (2.51–3.29)	<0.001
WBC	1.04 (1.01–1.06)	0.001	1.04 (1.02–1.07)	<0.001
Eosinophil ≥300 at screening	1.20 (1.05–1.36)	0.005	1.22 (1.06–1.42)	0.006

Risk estimate from negative binomial regression.

^*per 1 point increase in score,

^†per percentage point increase in FEV₁